CLASSICAL HODGKIN LYMPHOMA
Clinical trials for CLASSICAL HODGKIN LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new CLASSICAL HODGKIN LYMPHOMA trials appear
Sign up with your email to follow new studies for CLASSICAL HODGKIN LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Early trial of experimental cancer combo halted after just 6 patients
Disease control TerminatedThis early-phase study tested a new drug called PF-08046032, given alone or with another drug (sasanlimab), in adults with advanced lymphomas or solid tumors like lung cancer and melanoma. The trial aimed to check safety and find the right dose, but it was terminated early after …
Matched conditions: CLASSICAL HODGKIN LYMPHOMA
Phase: PHASE1 • Sponsor: Pfizer • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Promising cancer drug trial halted early – only 3 patients enrolled
Disease control TerminatedThis study tested a drug called tislelizumab, which helps the immune system fight cancer, against standard chemotherapy in people with Hodgkin lymphoma that returned or didn't respond to treatment. Only 3 people took part before the study was stopped early. Because of this, we do…
Matched conditions: CLASSICAL HODGKIN LYMPHOMA
Phase: PHASE3 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New shot for tough lymphomas shows early promise but trial halted
Disease control TerminatedThis early-stage trial tested a new drug called GEN3017 in 9 people with CD30-positive lymphomas (Hodgkin and non-Hodgkin) that had returned or stopped responding to standard treatments. The drug was given as a shot under the skin. The main goals were to check safety and find the…
Matched conditions: CLASSICAL HODGKIN LYMPHOMA
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Jun 27, 2026 07:51 UTC